| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.002 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.2 | 0.002 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.19 | 0.003 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.19 | 0.003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |